No abstract available
Keywords:
Gavreto; Retevmo; adverse effects; cabozantinib; dosage; drug interactions; efficacy; pralsetinib; safety; selpercatinib; thyroid cancer; vandetanib.
MeSH terms
-
Humans
-
Lung Neoplasms*
-
Neoplasms* / drug therapy
-
Protein Kinase Inhibitors
-
Proto-Oncogene Proteins c-ret / genetics
-
Pyrimidines
-
Thyroid Neoplasms*
Substances
-
pralsetinib
-
Pyrimidines
-
Protein Kinase Inhibitors
-
RET protein, human
-
Proto-Oncogene Proteins c-ret